Compare NPK & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | QURE |
|---|---|---|
| Founded | 1905 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 1.1B |
| IPO Year | 1994 | 2013 |
| Metric | NPK | QURE |
|---|---|---|
| Price | $135.05 | $17.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $44.92 |
| AVG Volume (30 Days) | 79.3K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | $141.42 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $77.63 | $7.76 |
| 52 Week High | $149.86 | $71.50 |
| Indicator | NPK | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 51.01 |
| Support Level | $128.22 | $13.52 |
| Resistance Level | $137.78 | $18.37 |
| Average True Range (ATR) | 5.24 | 1.28 |
| MACD | 0.01 | 0.47 |
| Stochastic Oscillator | 50.38 | 83.12 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.